WORLD JOURNAL OF ADVANCE
HEALTHCARE RESEARCH

Doaa Abdulelah Jawad*, Nawal Mehdi Firhan Alkhalidi and Ahmed Jassim Mohammed

ABSTRACT

Background: Metabolic dysfunction-associated fatty liver disease (MAFLD) is a common condition of the liver that is increasing in prevalence globally, this disease is often caused by insulin resistance, stress, and mitochondrial failure. Effective pharmaceuticals for treating diseases are limited, this has led to a focus on L-carnitine as it could help to support the metabolism of fatty acids and reduce liver fat. Aim: the aims of these study to assess the effectiveness of L-carnitine supplementation for treatment for MAFLD in adult patients. Method: A blinded, randomized trial was conducted on 50 individuals with MAFLD. Patient categories into two groups, those who received L-carnitine and who received a placebo, for a period of three months. Baseline and post-treatment parameters included lipids profile, assessment of liver enzymes (ALT, AST), ultrasound imaging, waist circumference, and. Statistical analyses employed t-tests, chi-square tests, and p values, with a significant level of p less than 0.05 being used. Results: The study results showed that L-carnitine supplementation of 500mg twice daily for 3 months significantly improved liver ultrasound scores, reduced ALT and AST levels, and lowered total cholesterol, LDL, and triglyceride levels compared to the placebo group. Additionally, there was not significance improvement in waist circumference in the L-carnitine group. These findings support L-carnitine’s potential benefits in managing MAFLD. Statistical significance was noted in most key measures, affirming the supplement’s efficacy. Conclusion: L-carnitine supplementation has a significant effect in MAFLD patients, it may therefore be a beneficial supplement to therapy. Future planned investigations should explore the optimal dosing and treatment duration for the greatest effect.